請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/41886
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 黃耀輝(Yaw-Huei Hwang) | |
dc.contributor.author | Ching-Chun Gong | en |
dc.contributor.author | 龔靜君 | zh_TW |
dc.date.accessioned | 2021-06-15T00:35:52Z | - |
dc.date.available | 2013-10-03 | |
dc.date.copyright | 2011-10-03 | |
dc.date.issued | 2011 | |
dc.date.submitted | 2011-08-22 | |
dc.identifier.citation | Abernathy CO, Liu YP, Longfellow D, Aposhian HV, Beck B, Fowler B, Goyer R,Menzer R, Rossman T, Thompson C. Arsenic: health Effects, mechanisms of actions, and research issues. Environ Health Perspect 1999;107:593-97.
Akesson A, Julin B, Wolk A. Long-term dietary cadmium intake and postmenopausal endometrial cancer incidence: a population-based prospective cohort study. Cancer Res 2008;68:6435-41. Ala Opas M, Tahvonen R. Concentrations of cadmium and lead in renal cell cancer. J. Trace Elem Med Biol 1995;9(3):176-80. Al-Sukhun S, and Hussain, M. Molecular biology of urothelial cell carcinoma. Crit Rev Oncol Hematol 2003;47:181-193. Amaral AF, Cymbron T, Gartner F, Lima M, Rodrigues AS. Trace metals and over-expression of metallothioneins in bladder tumoral lesions: a case-control study .BMC Veterinary Research 2009;24:24-29. Armstrong BG, Kazantzis G. Prostatic cancer and chronic respiratory and renal disease in British cadmium workers: a case control study. Br J Ind Med 1985;42:540-5. Aron M, Nguyen MM, Stein RJ, Gill IS. Impact of gender in renal cell carcinoma: an analysis of the SEER database. Eur Urol 2008;54:133–40. Barbier O, Jacquillet G, Tauc M, Cougnon M, Poujeol P. Effect of heavy metals on, and handling by, the kidney. Nephron Physiol 2005;99(4):105-10. Barceloux DG. Selenium. J Toxicol Clin Toxicol 1999;37(2):145-72. Batariova A, Spevackova V, Benes B, Cejchanova M, Smid J, Cerna M.Blood and urine levels of Pb, Cd and Hg in the general population of the Czech Republic and proposed reference values. Int J Hyg Environ Health 2006;209:359-66. Baumler J, Obersteg JI, Shafer R. Determination of the level of arsenic in human bodies. Dtsch Z Gesamte Gerichtl Med 1968;64:56-61. Braman RS, Foreback CC. Methylated forms of arsenic in the environment. Science 1973;182:1247-9. Beaumont JJ, Sedman RM, Reynolds SD, Sherman CD, Li LH, Sandy MS, Zeise L, Alexeeff GV. Cancer mortality in a chinese population exposed to hexavalent chromium in drinking water. Epidemiology 2008;19:12-23. Bernard A. Cadmium and its adverse effects on human health. Indian J Med Res 2008;128:557-564. Bernard A. Renal dysfunction induced by cadmium: biomarkers of critical effects. Biometals 2004;17:519–523. Boffetta P, Fontana L, Stewart P, Zaridze D, Szeszenia-Dabrowska N, Janout V, Bencko V, Foretova L, Jinga V, Matveev V, Kollarova H, Ferro G, Chow WH, Rothman N, van Bemmel D, Karami S, Brennan P, Moore LE. Occupational exposure to arsenic, cadmium, chromium, lead and nickel, and renal cell carcinoma: a caseecontrol study from Central and Eastern Europe. Occup Environ Med 2011;67:47-53. Byron, WR, Bierbower GW, Brouwer JB, Hansen WH. Pathologic changes in rats and dogs from two-year feeding of sodium arsenite or sodium arsenate. Toxicol Appl Pharmacol 1967;10:132-47. Carroll PR, Urothelial carcinoma: cancers of the bladder,ureter and renal pelvis. In: E.A. Tanagho and J.W. McAninch, eds. General Urology 1995;14:353-71. Calvo FB, Santos Junior D, Rodrigues CJ, Krug FJ, Marumo JT, Schor N, Bellini MH. Variation in the distribution of trace elements in renal cell carcinoma. Biol Trace Elem Res 2009;130(2):107-13. Chen CJ, Chuang YC, You SL, Lin TM, Wu HY. A retrospective study on malignant neoplasms of bladder, lung and liver in blackfoot disease endemic area in Taiwan. Br J Cancer 1986;53:399-405. Chen CJ, Kuo TL, Wu MM. Arsenic and cancers. Lancet 1988;1:414-5. Chen CJ, Wang CJ. Ecological correlation between arsenic level in well water and age-adjusted mortality from malignant neoplasms. Cancer Res 1990;50:5470-4. Chen KP, Wu HY. Epidemiologic studies on blackfoot diease in Taiwan, China. 6 Effect of the piped water supply on occurrence and dieasd progress of blackfoot diease . Journal of the Formosan Medical Association 1969;68:291-5 Chiou HY, Chiou ST, Hsu YH, ChouYL, Tseng CH, Wei ML, Chen CJ. Incidence of urothelial cell carcinoma and arsenic in drinking water a follow-up study of 8,102 residents in an arseniasis-endemic area in northeastern Taiwan. Am J Epidemiol 2001;153:411-8. Choiu HY, Hsueh YM, Liaw KF, Horng SF, Pu YS, Lin JS, Huang CH, Chen CJ. Incidence of internal cancers and ingested inorganic arsenic: a seven-year follow-up study in Taiwan. Cancer Research 1995;55:1296-300. Chou YH, Huang CH. Unusual clinical presentation of upper urothelial carcinoma in Taiwan. Cancer 1995;85:1342-4. Cherian M, Jayasurya A, Bay BH. Metallothioneins in human tumors and potential roles in carcinogenesis. Mut Res 2003;533:201-209. Clark LC, Combs GF Jr, Turnbull BW, Slate EH, Chalker DK, Chow J, Davis LS, Glover RA, Graham GF, Gross EG, Krongras A, Lesher JL Jr, Park HK, Sander BB Jr, Smith CL, Taylor JR. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. JAMA 1999;276:1957-63. Cohen HMF. Medical progress: renal cell carcinoma. New England Journal of Medicine. 2005;353:2477-90. Cooper WC, Gaffey WR. Mortality of lead workers. J Occup Med 1975;17(2):100-7. Cocco P, Hua F, Boffetta P, Carta P, Flore C, Flore V, Onnis A, Picchiri GF, Colin D. Mortality of Italian lead smelter workers. Scand J Work Environ Health 1997;23:15-23. Cooper WC, Wong O, Kheifets L. Mortality among employees of lead battery plants and lead-producing plants, 1947-1980. Scand J Work Environ Health 1985;11(5):331-45. Crump C, Crump K, Hack E, Luippold R, Mundt K, Liebig E, Panko J, Paustenbach D, Proctor D. Dose-response and risk-assessment of airborne hexavalent chromium and lung cancer mortality. Risk Anal 2003;23: 1147-63. Han CZ, Jing JX, Zhao XW, Guo JG, Zheng SM, Du LI. Serum and tissue levels of six trace elements and copper/zinc ratio in patients with cervical cancer and uterine myoma. Biol Trace Elem Res 2003;94(2):113-22. Dasanu CA, Ong-Bacay A, Codreanu I. Newer developments in the therapeutics of the urothelial cell carcinoma of renal pelvis. J Oncol Pharm Pract 2011;0:1-7. Dobrowolski Z, Drewniak T, Kwiatek W, Jakubik P. Trace Elements Distribution in renal cell carcinoma depending on stage of disease. Eur Urol 2002;42:475-480. Enterline PE, Day R, Marsh GM. Cancers related to exposure to arsenic at a copper smelter. Occup Environ Med 1995;52:28-32. Enterline PE, Henderson V L, Marsh GM. Exposure to arsenic and respiratory cancer, a reanalysis. Am J Epidemiol 1987;125:929-38. Ferlay J, Bray F, Pisani P, Parkin DM. Cancer incidence, mortality, and prevalence worldwide. In: GLOBOCAN 2002. Lyon: IARC Press, 2004. Fierz U. Catamnestic investigations of the side effects of therapy of skin diseases with inorganic arsenic. Dermatologica 1965;131:41–58. Friedberg EC. How nucleotide excision repair protects against cancer. Nature Rev. 2001;1. Gachot B, Tauc M, Morat L, Poujeol P. Zinc uptake by proximal cells isolated from rabbit kidney: Effects of cysteine and histidine. Pfl ugers Arch 1991;419:583-7. Gibb HJ, Lees PSJ, Pinsky PF, Rooney BC. Lung cancer among workers in chromium chemical production. Am J Ind Med 2000;38:115-126. Goulle JP, Mahieu L, Castermant, et al. Metal and metalloid multi-elementary ICP-MS validation in whole blood, plasma, urine and hair Reference values. Forensic Sci Int 2005;153:39-44. Goyer RA, Liu J, Waalkes MP. Cadmium and cancer of prostate and testis. Biometals 2004;17:555-8. Guo HR, Chiang HS, Hu H, Stuart RL, Richard R. Monson. Arsenic in drinking water and incidence of urinary cancers. Epidemiology 1997;8:545-50. Heitland P, Koster HD. Biomonitoring of 30 trace elements in urine of children and adults by ICP-MS. Clin Chim Acta 2006;365:310-8. Hsieh YF, Ling GC, Lu YB. Incidence of tumor of the renal pelvis in Taiwan. J Formos Med Assoc 1979;78:749-53. Hardell L, Wing AM, Ljungberg B, Dreifaldt AC, Degerman A, Halmans G. Levels of cadmium, zinc and copper in renal cell carcinoma and normal kidney. Eur J Cancer Prev 1994;3(1):45-8. Hodges NJ, Chipman JK. Down-regulation of the DNA-repair endonuclease 8-oxo-guanine DNA glycosylase 1 (hOGG1) by sodium dichromate in cultured human A549 lung carcinoma cells. Carcinogenesis 2002;23:55-60. Hopenhayn-Rich C, Biggs ML, Smith AH. Lung and kidney cancer mortality associated with arsenic in drinking water in Cordoba, Argentina. Int J Epidemiol 1998;27:561-9. Hsu PC, Guo YL. Antioxidant nutrients and lead toxicity. Toxicology 2002;180:33-44. Hsueh YM, Chiou HY, Huang YL, Wu WL, Huang CC, Yang MH, Lue LC, Chen GS, Chen CJ. Serum beta-carotene level, arsenic methylation capability, and incidence of skin cancer. Cancer Epidemiol 1997;6:589-596. Hsueh YM, Ko YF, Huang YK, Chen HW, Chiou HY, Huang YL, Yang MH, Chen CJ. Determinants of inorganic arsenic methylation capability among residents of the Lanyang Basin, Taiwan: arsenic and selenium exposure and alcohol consumption. Toxicol Lett 2003;137:49-63.. Huben RP, Mounzer AM, Murphy GP. Tumor grade and stage as prognostic variables in upper tract urothelial tumors. Cancer 1988;62:2016-20. Hughes MF. Arsenic toxicity and potential mechanisms of action. Toxicol Lett 2002;133:1-16. Hu J, Mao Y, White K. Renal cell carcinoma and occupational exposure to chemicals in Canada. Occup Med 2002;52:157-64. Hu Y, Su L, Snow ET. Arsenic toxicity is enzyme specific and its affects on ligation are not caused by the direct inhibition of DNA repair enzymes. Mutat Res 1998;408(3):203-18. IARC. Arsenic and arsenic compounds. IARC monographs on the evaluation of carcinogenic risk of chemicals to humans; Suppl 7. Overall evaluations of carcinogenicity: Updating of IARC monographs volumes 1-42. Lyon: France, World Health Organization, 1987;29-33. Ioachim EE, Charchanti AV, Stavropoulos NE, Athanassiou ED, Michael MC, Agnantis NJ. Localization of metallothionein in urothelial carcinoma of the human urinary bladder: an immunohistochemical study including correlation with HLA-DR antigen, p53, and proliferation indices. Anticancer Res 2001;21:1757–61. Ishinishi N, Yamamoto A, Hisanaga A, Inamasu T. Tumorigenicity of arsenic trioxide to the lung in Syrian golden hamsters by intermittent instillations. Cancer Lett 1983;21:141-7. Jarup L, Berglund M, Elinder CG, Nordberg G, Vahter M, Health effects of cadmium exposure- review of the literature and a risk estimate. Scand J Work Environ Health 1998;24:1–51. Jensen OM, Knudsen JB, McLaughlin JK, et al. The Copenhagen case-control study of renal pelvis and ureter cancer: role of smoking and occupational exposures. Int J Cancer 1988;41(4):557–61. Jia G, Sone H, Nishimura N, Satoh M, Tohyama C. Metallothionein (I/II) suppresses genotoxicity caused by dimethylarsinic acid. Int J Oncol 2004;25:325–33. Kitchin KT. Recent advances in arsenic carcinogenesis: modes of action, animal model systems, and methylated arsenic metabolites. Toxicol Appl Pharmacol 2001;172:249-261. Kanisawa M, Schroeder HA. Life term studies on the effect of trace elements on spontaneous tumors in mice and rats. Cancer Res 1969;29:892-5. Kasai H. Analysis of a form of oxidative DNA damage, 8-hydroxy-2'-deoxyguanosine, as a marker of cellular oxidative stress during carcinogenesis. Mutat Res 1997;387:147-63. Kirkali Z, Tuzel E. Urothelial cell carcinoma of the ureter and renal pelvis. Crit Rev Oncol Hematol 2003;47:155-69. Kolonel LN, Association of cadmium with renal cancer. Cancer 1976;37:1782-7. Kuo HW, Chen SF, Wu CC, Chen DR, Lee JH. Serum and tissue trace elements in patients with breast cancer in Taiwan. Biol Trace Elem Res 2002;89(1):1-11. Kusial RA, Springer J, Ritchie AC, Muller J. Carcinoma of the lung in Ontario gold miners: possible aetiological factors. Br J Ind Med 1991;48:808-17. Kwiatek WM, Drewniak T, Gajda M, Gałka M, Hanson AL, Cichocki T. Preliminary study on the distribution of selected elements in cancerous and non-cancerous kidney tissues. J Trace Elem Med Biol. 2002;16(3):155-60. Lalor GC. Review of cadmium transfers from soil to humans and its health effects in the Jamaican environment. Sci Total Environ 2008;400:162-172. Lee-Feldstein A. Arsenic and respiratory cancer in human: follow-up of copper smelter employees in Montana. J Natl Cancer Inst 1983;70:601-9. Lee-Feldstein A, Cumulative exposure to arsenic and its relationship to respiratory cancer among copper smelter employees. J Occup Med 1986;28:296-302. Levi F, Ferlay J, Galeone C, Lucchini F, Negri E, Boyle P, La Vecchia C. The changing pattern of kidney cancer incidence and mortality in Europe. BJU Int 2008;101:949–58. Lin CN, Wang LH, Shen KH. Determining urinary trace elements (Cu, Zn, Pb, As, and Se) in patients with bladder cancer. Journal of Clinical Laboratory Analysis 2009;23:192-5. Lin SM, Chiang CF, Yang MH. Arsenic concentration in the urine of patients with blackfoot disease and bowen's disease. Biol Trace Elem Res 1985;8:11-8. Lipworth L, Tarone RE, McLaughlin JK. The epidemiology of renal cell carcinoma. J Urol 2006;176: 2353-8. Mandel JS, McLaughin JK, Schlehofer B, Mellemgaard A, Helmert U, Lindblad P, McCredie M, Adami HO. International renal-cell cancer study.IV. Occupation. Int J Cancer 1995;61:601-5. Magos L. Epidemiological and experimental aspects of metal carcinogenesis: physicochemical properties, kinetics, and the active species. Environ Health Persp 1991;95:157-89. McElroy JA, Shafer MM, Trentham-Dietz A, Hampton JM, Newcomb PA. Cadmium exposure and breast cancer risk. J Natl Cancer Inst 2006;98:869-73. McElroy JA, Shafer MM, Trentham-Dietz A, Hampton JM, Newcomb PA. Urinary cadmium levels and tobacco smoke exposure in women age 20-69 years in the United States. J Toxicol Environ Health A 2007;70(20):1779-82. McGee HM, Woods GM, Bennett B, Chung RS. The two faces of metallothionein in carcinogenesis: photoprotection against UVR-induced cancer and promotion of tumour survival. Photochem 2010;9:586-596. McLaughlin WJB, Devesa SS, Fraumeni JF. Renal cancer. In: Schottenfeld D, Fraumeni JF, eds. Cancer epidemiology and prevention, New York : Oxford Univ. Press, 1996;1142-55. Mehmet Y. Comprehensive comparison of trace metal concentrations in cancerous and non-cancerous human tissues. Curr Med Chem 2006;13:2513-25. Melamed MR, Reuter VE. Pathology and staging of urothelial tumors of the kidney and ureter. Urol Clin North Am 1993;20: 333-47. Meliker JR, Wahl RL, Cameron LL, Nriagu JO. Arsenic in drinking water and cerebrovascular disease, diabetes mellitus, and kidney disease in Michigan: a standardized mortality ratio analysis. Environ Health 2007;6;1-11. Mei N, Lee J, Sun X, Xing JZ, Hanson J, Le XC, Weinfeld M. Genetic predisposition to the cytotoxicity of arsenic: the role of DNA damage and ATM. FASEB J 2003;17(15):2310-2. Miller WH, Schipper HM, Lee JS, Singer J, Waxman S. Mechanisms of action of arsenic trioxide. Cancer Res 2002;62:3893-903. Moffatt P, Denizeau F. Metallothionein in physiological and physiopathological processes. Drug Metab Rev 2003;29:261-307. Moulis JM. Cellular mechanisms of cadmium toxicity related to the homeostasis of essential metals. Biometals 2010;23(5):877-96. Muller I, Helmers E, Barchet R, Schweinsberg F. Cadmium concentration in the renal cortex of kidney tumor patients and controls. J Trace Elem Electrolytes Health Dis 1994;8(3-4):173-6. Norbury CJ, Hickson ID. Cellular responses to DNA damage. Annu Rev Pharmacol Toxico. 2001;41:367-401. Nielsen AE, Bohr A, Penkowa M. The balance between life and death of cells: roles of metallothioneins. Biomarker Insights 2007;2:99-111. Nordberg GF, Kjellstrom T, Nordberg M. Kinetics and Metabolism. In: Friberg L, Elinder CG, Kjellstrom T, Nordberg GF eds. Cadmium and Health volume 1: Exposure, Dose and Metabolism. Boca Raton: CRC Press, 1985;103-78. Olgac S, Mazumdar M, Dalbagni G, et al. Urothelial carcinoma of the renal pelvis: a clinicopathologic study of 130 cases. Am J Surg Pathol 2004;28:1545-1552. Olsson IM, Bensryd I, Lundh T, Ottosson H, Skerfving S, Oskarsson A. Cadmium in blood and urine--impact of sex, age, dietary intake, iron status, and former smoking--association of renal effects. Environ Health Perspect 2002;110(12):1185-90. Orlowski C, Piotrowski JK. Biological levels of cadmium and zinc in the small intestine of non-occupationally exposed human subjects. Hum Exp Toxicol 2003;22:57-63. Parent ME, Hua Y, Siemiatycki J. Occupational risk factors for renal cell carcinoma in Montreal. Am J Ind Med 2000;38:609-18. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108. Parrish AR, Zheng XH, Turney KD, Younis HS, Gandolfi AJ. Enhanced transcription factor DNA binding and gene expression induced by arsenite or arsenate in renal slices. Toxicol Sci 1999;50: 98-105. Partanen T, Heikkila P, Hernberg S, Kauppinen T, Moneta G, Ojajarvi A. Renal cell cancer and occupational exposure to chemical agents. Scand. J. Work Environ. Health 1991;17:231-9. Pedersena M, Larsen A, Stoltenbergb M, Penkowa M. The role of metallothioneinin oncogenesis and cancerprognosis. Progress in histochemistry and cytochemistry 2009;44:29-64. Perez RD, Rubio M, Perez CA, Eynard AR, Bongiovanni GA. Study of the effects of chronic arsenic poisoning in rat kidneys by means of synchrotron microscopic x-ray fluorescence analysis. X-Ray spectrometry 2006;35:352-358. Pershagen G, Bjorklund NE. On the pulmonary tumorigenicity of arsenic trisulfide and calcium arsenate in hamsters. Cancer Lett 1985;27:99-104. Pershagen G, Nordberg G, Bjorklund NE. Carcinomas of the respiratory tract in hamsters given arsenic trioxide and/or benzo(a)pyrene by the pulmonary route. Environ Res 1984;34:227-241. Penkowa M, Caceres M, Borup R, Nielsen FC, Poulsen CB, Quintana A, Molinero A, Carrasco J, Florit S, Giralt M, Hidalgo J. Novel roles for metallothionein-I+II (MT-I+II) in defense responses, neurogenesis, and tissue restoration after traumatic brain injury: insights from global gene expression profiling in wild-type and MT-I+II knockout mice. J Neurosci Res 2006;84:1452–74. Pesch B, Haerting J, Ranft U, Klimpel A, Oelschlagel B, Schill W, Occupational risk factors for renal cell carcinoma: agent-specific results from a case-control study in Germany. MURC study group. Multicenter urothelial and renal cancer study. Int J Epidemiol 2000;29:1014 – 24. Pommer W, Bronder E, Klimpel A, et al. Urothelial cancer at different tumour sites: role of smoking and habitual intake of analgesics and laxatives. Results of the Berlin Urothelial Cancer Study. Nephrol Dial Transplant 1999;14(12):2892–7. Pu YS, Yang SM, Huang YK, Chung CJ, Huang SK, Chiu AW, Yang MH, Chen CJ, Hsueh YM. Urinary arsenic profile affects the risk of urothelial carcinoma even at low arsenic exposure. Toxicology and Applied Pharmacology 2007;218:99-106. Rahman M, Wingren G, Axelson O. Diabetes mellitus among Swedish art glass workers: an effect of arsenic exposure? Scand J Work Environ Health 1996;22:146-9. Rajaraman P, Stewart PA, Samet JM, Schwartz BS, Linet MS, Zahm SH, Rothman N, Yeager M, Fine HA, Black PM, Loeffler J, Shapiro WR, Selker RG, Inskip PD. Lead, genetic susceptibility, and risk of adult brain tumors. Cancer Epidemiol Biomark Prev 2006;15:2514-20. Rossman TG. Mechanism of arsenic carcinogenesis: an integrated approach. Mutat Res 2003;533:37-65. Rousseau MC, Parent ME, Nadon L, Latreille B, Siemiatycki J. Occupational exposure to lead compounds and risk of cancer among men: a population-based case-control study. Am J Epidemiol 2007;166:1005-1014. Sabolić I. Common mechanisms in nephropathy induced by toxic metals. Nephron Physiology 2006;104:107-114. Sabolić I, Breljak D, Skarica M, Herak-Kramberger CM. Role of metallothionein in cadmium traffic and toxicity in kidneys and other mammalian organs. Biometals 2010;23:897-926. Sato M, Kondoh M. Recent studies on metallothionein: protection against toxicity of heavy metals and oxygen free radicals. Tohoku J Exp Med 2002;196:9-22. Schlehofer B, Heuer C, Blettner M, Niehoff D, Wahrendorf J. Occupation, smoking and demographic factors, and renal cell carcinoma in Germany. Int J Epidemiol 1995;24:51-7. Selevan SG, Landrigan PJ, Stern FB, Jones JH. Mortality of lead smelter workers. Am J Epidemiol 1996;122:673-83. Shamberger RJ, Tytko SA, Willis CE. Antioxidants and cancer: part VI. Selenium and age-adjusted human cancer mortality. Arch Environ Health 1976; 31:231-5. Silbergeld EK, Waalkes M, Rice JM. Lead as a carcinogen: experimental evidence and mechnisms of action. Am J Ind Med 2000;38:316-23. Soria EA, Goleniowski ME,CanteroJJ, Bongiovanni GA. Antioxidant activity of different extracts of Argentinean medicinal plantsaga instarsenic induced toxicityinrenalcells. Hum Exp Toxicol 2008;27:341-346.. Spalholz JE. On the nature of selenium toxicity and carcinostatic activity. Free Radical Biological and Medicine 1994;17:45-64. Straif K, Benbrahim-Tallaa L, Baan R, Grosse Y, Secretan B, Ghissassi F, Bouvard V, Guha N, Freeman C, Galichet L, Cogliano V. A review of human carcinogens-part C: metals, arsenic, dusts, and fibres. Lancet Oncol 2009;0:453-4. Stafford H, Saltzatein SL, Shimasaki S, Sanders C, Downs TM, Sadler GR. Racial/ethnic and gender disparities in renal cell carcinoma incidence and survival. J Urol 2008;179:1704-08. Steenland K, Selevan S, Landrigan P. The mortality of lead smelter workers: an update. Am J Public Health 1992;82:1641-4. Sun M, Thuret R, Firas Abdollah F, Lughezzani G, Schmitges J, Tian Z, Shariat SF, Montorsi F, Patard JJ, Perrotte P, Karakiewicz PI. Age-adjusted incidence, mortality, and survival rates of stage-specific renal cell carcinoma in North America: a trend analysis. Eur Urol 2011;59:135-41. Tapio S, Grosche B. Arsenic in the aetiology of cancer. Mutat Res 2006;612:215-46. Thevenod F. Nephrotoxicity and the proximal tubule. Nephron Physiol Insights from cadmium 2003;93(4):87-93. Thirumoorthy N, ManisenthilKumar KT, ShyamSundar A, Panayappan L, Chatterjee M. Metallothionein: an overview. World J Gastroenterol 2007;13:993–6. Thorgeirsson UP, Dalgard DW, Reeves J, Adamson RH. Tumor incidence in a chemical carcinogenesis study of nonhuman primates. Reg Toxicol Pharmacol 1994;19:130-51. Tomasek L, Darby SC. Recent results from the study of west Bohemian uranium miners exposed to radon and its progeny. Environ Health Perspect 1995;103:55-7. Tsai SM, Wang TN, Ko YC. Mortality for certain disease in areas with high levels of arsenic in drinking water. Arch Environ Health 1999;54:186-93. Vahter M, Berglund M, As kesson A, LideHn C. Metals and women's health. Environmental Research Section A 2002;88:145-155. Vahter M. Mechanisms of arsenic biotransformation. Toxicology 2003;181:211-7. Valko M, Morris H, Cronin MTD. Metals, toxicity and oxidative stress. Curr Med Chem 2005;12(10):1161-208. Van Wijngaarden E, Dosemeci M. Brain cancer mortality and potential occupational exposure to lead: findings from the National Longitudinal Mortality Study, 1979-1989. Int J Cancer 2006;119:1136-1144. Viren JR, Silvers A. Unit risk estimates for airborne arsenic exposure: an updated view based on recent data from two copper smelter cohorts. Regul Toxicol Pharmacol 1994;20:125-138. Waalkes MP. Cadmium carcinogenesis. Mutat Res 2003;533:107-20. Waalkes MP. Cadmium carcinogenesis in review. Journal of Inorganic Biochemistry 2000;79(1-4):241-4. Waalkes MP, Anver MR, Diwan BA, Chronic toxic and carcinogenic effects of oral cadmium in the noble (NBL/Cr) rat: induction of neoplastic and proliferative lesions of the adrenal, kidney, prostate, and testes. J Toxicol Environ Health 1999;58:199 - 214. Wang TC, Jan KY, Wang SS, Gurr JR. Trivalent arsenicals induce lipid peroxidation, protein carbonylation, and oxidative DNA damage in human urothelial cells. Mutation Research 2007;615:75-86. Wang L, Li JJ, Li JG, Liu ZP. Efects of lead and/or cadmium on the oxidative damage of rat kidney cortex mitochondria. Biol Trace Elem Res 2010;137:69-78. Wilson RT, Donahue M, Gridley G, Adami J, Ghormli L, Dosemeci M. Shared occupational risks for transitional cell cancer of the bladder and renal pelvis among men and women in Sweden. Am J Ind Med 2008;51:83-99. Wolf C, Strenziokb R, Kyriakopoulosa A. Elevated metallothionein-bound cadmium concentrations in urine from bladder carcinoma patients, investigated by size exclusion chromatography-inductively coupled plasma mass spectrometry. Analytica Chimica Acta 2009;631:218-22. Wong O, Harris F. Cancer mortality study of employees at lead battery plants and lead smelters. Am J Ind Med 2000;38(3):255-70:1947-95. Wu MM, Kou TL, Hwang YH, Chen CJ. Dose-response relation between arsenic concentration in well water and mortality from cancers and vascular diseases. Am J Epidemiol 1989;130:1123-32. Yamamoto A, Hisanaga A, Ishinishi N. Tumorigenicity of inorganic arsenic compounds following intratracheal instillations to the lungs of hamsters. Int J Cancer 1987;40:220-3. Yamauchi H, Takahashi K, Mashiko M, Yamamura Y. Biological monitoring of arsenic exposure of gallium arsenide and inorganic arsenic-exposed workers by determination of inorganic arsenic and its metabolites in urine and hair. Am Ind Hyg Assoc J 1989;50:606-12. Yang L, Broaddus VC,Scavo LM, Ernst JD, Boylan AM. Asbestos induces apoptosis of human and rabbit pleural mesothelial cells via reactive oxygen species. J Clin Invest 1996 Nov 1;98(9):2050-9. Yang MH, Chen KK, Yen CC, Wang WS, Chang YH, Huang WJ, Fan FS, Chiou TJ, Liu JH, Chen PM. Unusually high incidence of upper urinary tract urothelial carcinoma in Taiwan. Urology 2002;59(5):681-7. Yang CY, Chiu HF, Wu TN, Chuang HY, Ho SC. Reduction in kidney cancer mortality following installation of a tap water supply system in an arsenic-endemic area of Taiwan. Arch Environ Health 2004;59:484-8. Yoshida T, Yamauchi H, Sun GF. Chronic health effects in people exposed to arsenic via the drinking water:dose-response relationships in review. Toxicol Appl Pharmacol 2004;198:243-52. Yoshizawa K, Willett WC, Morris SJ, Stampfer MJ, Spiegelman D, Rimm EB, Giovannucci E. Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer. J Natl Cancer 1998;90:1219-24. Yuan Y, Marshall G, Ferreccio C. Kidney cancer mortality: fifty-year latency patterns related to arsenic exposure. Epidemiology 2010;21(1):103-8. Zachara BA, Marchaluk-Wiśniewska E, Maciag A, Pepliński J, Skokowski J, Lambrecht W. Decreased selenium concentration and glutathione peroxidase activity in blood and increase of these parameters in malignant tissue of lung cancer patients. Lung 1997;175(5):321-32. 王明光:實用儀器分析。台北:合記書局,2003。 司寇克,林敬二譯:儀器分析。第五版。台北:美亞書版股份有限公司,1999。 江博暉、江博煌、吳文正、康智雄:醫學新知2:尿路上皮細胞癌新知。高雄:人生書局,2006;21-27。 行政院衛生署:九十八年死因統計。台北:行政院衛生署,2010。 行政院衛生署:台灣國民營養健康狀況變遷調查。台北:行政院衛生署,2008。Available at: <http :// food.doh.gov.tw/FOODNEW/research/NationalResearch.aspx>,accessed on December, 2009。 李宜映:慢性尿毒症大鼠腎臟處理銅的研究。台北:國立陽明大學生理學研究所,2010。 林和靜:利用Microbore-HPLC-ICP-MS連線分析系統進行尿中硒物種的分析研究。新竹:國立清華大學原子科學研究所碩士論文,2001。 吳宗穎:腎臟系統簡易學。台北:合記書局,2005。 施惟量:砷暴露者與抽菸者移行上皮細胞癌之p53基因突變譜之比較研究。台北:國立台灣大學流行病學研究所碩士論文,2001。 陳由瑄:食用牡蠣後尿中砷代謝物分布之變異性。台北:國立台灣大學職業醫學與工業衛生研究所碩士論文,2003。 陳健文:以病例對照研究法探討成藥對腎功能影響。台北:國立台灣大學預防醫學研究所碩士論文,2006。 詹智遠: 環境微生物處理重金屬之研究。花蓮:國立東華大學生物技術研究所碩士論文,1999。 賴敏裕:臨床腎臟病學-檢查、診斷、疾病各論。台北:合紀圖書出版社,2005。 | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/41886 | - |
dc.description.abstract | 國外許多流行病學研究中皆發現金屬暴露與癌症的關係,國內也有研究發現砷的暴露與尿路上皮細胞癌之間有顯著的劑量反應關係存在。動物實驗中,暴露砷、鎘、鉛與鎳等也被報導與腎臟腫瘤發展有關,但目前金屬暴露在腎臟癌發生機制所扮演的角色仍未有定論。因此,本研究目的為探討多元素在腎臟癌個案尿中及腎皮質、腎盂、輸尿管中之濃度分布,期望能進一步了解金屬暴露與腎臟癌發生的關係。本研究中招募了41名來自於台大醫院泌尿部的尿路上皮細胞癌與11名腎細胞癌個案,還有8名對照個案。腎臟癌個案在經過病理學的判定確認後,將依照TNM癌症分類系統進行癌症病程的分級。另以問卷收集個案之年齡、身高、體重、職業、抽菸、規律喝酒、飲食習慣、中草藥使用與家族及病史等資料。腎皮質、腎盂、輸尿管組織樣本經由密閉式之微波消化系統,再由ICP-MS進行正常組織與腫瘤組織樣本中金屬濃度之分析。尿液樣本先經過0.45 μm的濾膜過濾,再透過ICP-MS分析尿中金屬之濃度。研究結果顯示,不同癌症病程的腎臟癌病人,尿中各種金屬濃度差異在統計上未達顯著。腎皮質及腎盂正常組織中砷、鎘、錳與銅濃度高於同部位腫瘤組織,其中鎘在上述兩腎臟部位正常組織皆顯著高於相對腫瘤組織,砷與鍶在腎皮質正常組織中濃度顯著比同部位腫瘤組織高。輸尿管腫瘤組織中砷、鎘、錳與銅濃度較正常組織高,其中砷與鎘在輸尿管正常與腫瘤兩組織間差異達統計上顯著。總結來說,各種金屬在腎皮質、腎盂與輸尿管的正常組織與腫瘤組織中濃度分布不同,推測可能是由於腫瘤細胞快速增生或金屬硫蛋白在腫瘤細胞中大量表現所導致,確實的形成機制亟待未來進一步研究探討。 | zh_TW |
dc.description.abstract | Several epidemiological studies reported the association between trace metals exposure and cancers. In Taiwan, a significant dose-response relationship between arsenic exposure and urothelial cell carcinoma was also demonstrated. Besides, animal studies showd tumor growth in animals exposed to arsenic, cadmium, lead and nickel. However, the roles of trace metals in the development of kidney cancer are unclear. The purpose of this study was to characterize the distribution of trace metals in urine and in renal cortex, pelvis, and ureter of the study subjects to further explore the relationship between trace metals and kidney cancer. In this study, 41 urothelial cell carcinoma (UCC) cases, 11 renal cell carcinoma (RCC) cases, and 8 controls were obtained from the Urological Department of the National Taiwan University Hospital. All UCC and RCC subjects were histologically diagnosed and classified according to the TNM classification system. Questionnaire was admintered to collect individual’s information, such as age, body height, weight, smoking history, occupation, alcohol drinking, dietary habit, herbal medicine uses, and familial disease history. Normal and tumor tissue samples of renal cortex, renal pelvis, and ureter were decomposed by using a microwave-assisted method in closed vessels. The inductively coupled plasma mass spectrometry was used to determine the contents of trace metals in normal and tumor renal tissue. Urine sample was first filtered through a 0.45-μm membrane prior to being analysed by ICP-MS. In this study no significant difference was found in urinary metal levels of kidney cancer cases among different stages. With respect to trace metals in renal tissues, the concentrations of cadmium in normal tissues were significantly higher than in tumor tissues of both renal cortex and pelvis, respectively, whereas the concentrations of arsenic and strontium in normal tissues were significantly higher than in tumor tissue only in renal cortex. For ureter, the concentrations of arsenic and cadmium in tumor tissue were significantly higher than in normal tissue, while those of manganese and copper in tumor tissue were also higher, though not statisticaly significantly, than in normal tissue. In summary, the concentrations of various trace metals in tumor and normal tissues differed in cortex, pelvis, or ureter, which might be caused by the fast proliferation of tumor cell or the over-expression of metallothionein in tumor cell. However, the real mechanism is still warrants further studies. | en |
dc.description.provenance | Made available in DSpace on 2021-06-15T00:35:52Z (GMT). No. of bitstreams: 1 ntu-100-R98841010-1.pdf: 647798 bytes, checksum: c13ef7135ee879e18f014a97bc7269d5 (MD5) Previous issue date: 2011 | en |
dc.description.tableofcontents | 第一章 前言1
1.1研究背景及研究目的1 第二章 文獻探討3 2.1腎臟癌簡介3 2.1.1腎細胞癌(renal cell carcinoma, RCC)3 2.1.2尿路上皮細胞癌(urothelial cell carcinoma, UCC)4 2.2金屬與癌症的關係4 2.2.1砷6 2.2.2鎘8 2.2.3鉛9 2.2.4鉻10 2.2.5硒10 2.2.6錳11 2.3金屬與腎臟癌的關係11 2.4分析方法13 2.4.1 ICP-MS介紹13 第三章 材料與方法15 3.1研究對象15 3.2問卷設計15 3.3泌尿道癌症分類系統(TNM)16 3.4生物樣本收集及處理16 3.4.1尿液樣本收集16 3.4.2組織樣本收集16 3.4.3尿液樣本測定與前處理17 3.4.4組織樣本測定與前處理17 3.4.5尿液多元素分析檢量線配製18 3.4.6組織多元素分析檢量線配製19 3.5儀器設備20 3.6試藥與試劑20 3.7分析方法之品質管控20 3.7.1偵測極限20 3.7.2添加標準品分析21 3.7.3標準參考樣本分析21 3.8統計分析21 第四章 結果22 4.1受試者基本資料22 4.2尿液中多元素金屬之分布情形24 4.2.1尿路上皮細胞癌個案尿液中多元素金屬分布與癌症病程之關係26 4.2.2腎細胞癌個案尿液中多元素金屬分布與癌症病程之關係28 4.2.3不同性別、年齡層與兩種類型腎臟癌個案之尿液金屬濃度分布30 4.3組織中多元素金屬之分布情形32 4.3.1正常與腫瘤組織中金屬濃度差異32 4.3.2腎臟正常組織、腫瘤組織之不同部位中金屬濃度比較34 4.3.3腎臟各部位正常組織、腫瘤組織與對照個案各部位組織之金屬濃度比較36 第五章 討論40 5.1尿液中多元素金屬分布與癌症病程之關係探討40 5.1.1砷在尿液中的分布與癌症病程之關係41 5.1.2 不同性別尿液中多元素濃度分布44 5.2多元素在腎臟癌個案組織中累積之情形45 5.2.1腎臟癌個案正常組織與腫瘤組織中多種金屬元素濃度差異45 5.2.1.1腎皮質及腎盂正常組織與相對腫瘤組織中多種金屬濃度差異45 5.2.1.2探討腎皮質正常組織中砷、鎘濃度顯著高於腫瘤組織之可能原因45 5.2.1.3比較輸尿管與腎皮質在正常組織與腫瘤組織中各種金屬濃度差異之探討46 5.2.1.4硒在不同部位的正常組織與腫瘤組織中濃度分布不同之探討47 5.2.2腎臟癌個案與對照個案正常組織與腫瘤組織中多種金屬濃度47 5.2.2.1腎細胞癌個案與對照個案在正常組織與腫瘤組織中濃度分布之探討48 5.4本研究之限制49 第六章 結論50 第七章 參考文獻51 表目錄 表 1 ICP-MS元素分析之同位素干擾來源14 表 2 Microwave進行組織樣本消化之參數設定17 表 3 ICP-MS進行尿液樣本及組織樣本分析之參數設定 17 表 4尿液中多種金屬元素分析檢量線配製18 表 5組織樣本多種金屬元素分析檢量線配製19 表 6受試者個案基本資料23 表 7 46名不同癌症病程腎臟癌個案及7名對照個案尿液中之多種金屬元素濃度分布情形25 表 8 37名不同癌症病程移行性上皮細胞癌個案及7名對照個案尿液中之多種金屬元素濃度分布情形27 表 9 9名不同癌症病程腎細胞癌個案及7名對照個案尿液中之多種金屬元素濃度分布情形29 表 10不同性別、年齡層與腎臟癌類型尿液多種屬元素濃度分佈31 表 11腎臟癌個案正常與腫瘤組織中之多種金屬元素濃度差異比較33 表 12腎臟不同部位正常組織、腫瘤組織中其各種金屬濃度差異之比較35 表 13腎細胞癌個案腎皮質正常及腫瘤組織與對照個案腎皮質組織中多種金屬元素濃度之比較37 表 14腫瘤部位於腎盂之尿路上皮細胞癌個案腎盂正常及腫瘤組織與對照個案腎盂組織中多種金屬元素濃度之比較38 表 15腫瘤部位於輸尿管之尿路上皮細胞癌個案輸尿管正常及腫瘤組織與對照個案輸尿管組織中多種金屬元素濃度之比較39 表 16移除離群植後續分析腎臟癌個案、尿路上皮細胞癌個案與腎細胞癌個案尿中砷濃度分布情形43 附錄 附錄1、收案問卷64 附錄2、檢量線70 | |
dc.language.iso | zh-TW | |
dc.title | 腎細胞癌及尿路上皮細胞癌與尿中及腎臟皮質、腎盂、輸尿管組織中金屬元素關係之探討 | zh_TW |
dc.title | Investigation on the Association of Renal and Urothelial Cell Carcinoma with Metal Levels in Urine and Tissues of Renal Cortex, Pelvis,and Ureter | en |
dc.type | Thesis | |
dc.date.schoolyear | 99-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 王榮德(Jung-Der Wang),陳保中(Pau-Chung Chen),王碩盟(Shuo-Meng Wang) | |
dc.subject.keyword | 重金屬,尿,腎皮質,腎盂,輸尿管,腎臟癌,尿路上皮細胞癌, | zh_TW |
dc.subject.keyword | Heavy metals,Urine,Renal cortex,Renal pelvis,Ureter,Kidney cancer,Urothelial cell carcinoma, | en |
dc.relation.page | 74 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2011-08-22 | |
dc.contributor.author-college | 公共衛生學院 | zh_TW |
dc.contributor.author-dept | 職業醫學與工業衛生研究所 | zh_TW |
顯示於系所單位: | 職業醫學與工業衛生研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-100-1.pdf 目前未授權公開取用 | 632.62 kB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。